Aplastic Anemia
Guillermo Montalban Bravo, MD
Institution
UT MD Anderson
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Myelomonocytic Leukaemia (CMML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
David Young, MD, PhD
Institution
NIH
Primary Disease Area of Focus
Aplastic Anemia
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pediatric
About
Dr. Young is a board-certified Pediatrician and Pediatric Hematologist and Oncologist who studies the genetics, molecular biology, and clinical management and treatment of bone marrow failure syndromes, myeloid malignancies, and other genetic disorders. He oversees clinical trials in aplastic anemia and Diamond-Blackfan anemia while also working with non-human primate models of disease and preclinical development. He also serves as the Medical Director for the RUNX1 Natural History Program of the National Human Genome Research Institute. Dr. Young received a B.Sc. from the University of Notre
Enrico Attardi, MD, PhD
Institution
University of Rome Tor Vergata
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
About
MD, PhD. My main scientific interests concern germline predisposition to bone marrow failures and myeloid neoplasms, particularly to myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). I am also deeply intrigued by the intersection of inborn errors of immunity (IEIs) and hemopathies.
Prognostic significance of PNH clones in aplastic anemia treated with immunosuppression or allogeneic HSCT: a 20-year single-center experience
Original Publication Date
Article Source
External Web Content
Background Paroxysmal nocturnal hemoglobinuria (PNH) clones are detected in up to 60% of patients with aplastic anemia (AA); however, their prognostic impact remains incompletely defined, particularly in the context of frontline immunosuppressive therapy (IST) or allogeneic…
How I select hematopoietic cell donors in the era of posttransplant cyclophosphamide
Original Publication Date
Article Source
External Web Content
Abstract Selection of a hematopoietic progenitor cell donor for allogeneic hematopoietic cell transplantation (HCT) is essential for treatment planning; however, the parameters that define an “optimal” donor in the modern era are not well defined. Historically, donor-recipient…
Impact of Modern Strategies for Graft-Versus-Host Disease Prophylaxis on Relapse Risk in Matched-Sibling or Unrelated Donor Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis of Randomized Trials
Original Publication Date
Article Source
External Web Content
ABSTRACT Regimens combining calcineurin inhibitors with methotrexate or mycophenolate have been the backbone for graft-versus-host disease (GVHD) prophylaxis. Early studies highlighted a delicate dose–response balance. The inclusion criteria comprised randomized clinical trials…
Expert Opinion on the Diagnosis and Treatment of Hematologic Malignancies During Pregnancy
Original Publication Date
Article Source
External Web Content
Abstract The diagnosis and treatment of hematologic malignancies has undergone significant advancements over the past few decades, resulting in enhanced outcomes. For hematologic malignancies diagnosed during pregnancy, this poses new questions. As possibilities continue to…
American Society of Hematology 2026 Guidelines for the Diagnosis and Management of Severe and Very Severe Acquired Aplastic Anemia
Original Publication Date
Article Source
External Web Content
Background: Aplastic anemia is a rare, life-threatening condition marked by pancytopenia and bone marrow hypocellularity. Despite therapeutic advances, clinical practice remains variable, and uncertainties persist regarding diagnosis and optimal management. To address these gaps…
Corticosteroid resistance is predetermined by early immune response dynamics at acute graft-versus-host disease onset
Original Publication Date
Article Source
External Web Content
Patients who receive hematopoietic stem cell transplants are at risk of developing graft-versus-host disease (GVHD), where the immune cells descended from the transplanted stem cells attack the transplant recipient’s own tissues. Acute GVHD (aGVHD) is often treated with…